Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM31NJU)

• Drug Name: ABY-025 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM31NJU

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[3]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[4]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[6]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[7]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[8]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[9]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[10]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[11]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Enhancer	[2]

References

• [1] ClinicalTrials.gov (NCT01858116) PET Study of Breast Cancer Patients Using [68Ga]ABY-025. U.S. National Institutes of Health.
• [2] Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8.
• [3] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [5] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] Clinical pipeline report, company report or official report of Roche (2009).
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.